Company Overview - Aspire Biopharma, Inc. is a privately held, early-stage biopharmaceutical technology company founded in 2021, focused on developing and marketing disruptive drug delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements [20] - The company is headquartered in Humacao, Puerto Rico, and has developed a Novel Soluble Formulation that addresses emergencies, drug efficacy, dosage management, patient compliance, and rapid response and absorption time [5][20] Technology and Product Development - Aspire has filed a patent application with the USPTO for a new technology and aspirin formulation aimed at creating soluble, pH neutral, fast-acting powder products [1] - The company's lead candidate, Instaprin™, is a granular or powder formulation of soluble, pH neutral, fast-acting aspirin designed for cardiology emergencies and pain management [10] - Instaprin™ offers benefits such as instant absorption for quick treatment impact and high dose absorption for various pain management scenarios [10] - Aspire is also developing a proprietary Viagra/Cialis combination product, bi-hormonal drugs, traumatic brain injury drugs, and thyroid drugs among others [3] Business Combination and Growth Strategy - Aspire Biopharma has signed a non-binding letter of intent with PowerUp Acquisition Corp. for a potential business combination, which aims to increase the company's visibility and access to capital [8][11] - The combined public company is expected to be listed on a national securities exchange following the consummation of the business combination [8] - The company is in the process of broadening its patent portfolio internationally and filing additional patents for new drugs under development [1] Regulatory and Market Position - Aspire plans to file a 505(b)(2) New Drug Application (NDA) with the FDA for Instaprin™, which allows referencing safety and efficacy data from already approved drugs to expedite the approval process [10] - The company aims to address the limitations of current aspirin applications, particularly side effects from acidity, by utilizing its innovative delivery system that allows rapid sublingual absorption [2][9]
Aspire Biopharma, Inc. Signs Letter of Intent to Create a Publicly Listed, Drug Delivery Company Through a Business Combination with PowerUp Acquisition Corp.